Kimberly S. Smythe
YOU?
Author Swipe
View article: B cell responses specific for polyomavirus-derived oncoprotein are predictive of Merkel cell carcinoma tumor control
B cell responses specific for polyomavirus-derived oncoprotein are predictive of Merkel cell carcinoma tumor control Open
Merkel cell carcinomas typically arise from clonal integration of the Merkel cell polyomavirus. Immunogenic viral oncoproteins then lead to tumorigenesis. Oncoprotein-specific T cells are essential for anti-MCC immunity, but it is unclear …
View article: Quantitative benchmarking of nuclear segmentation algorithms in multiplexed immunofluorescence imaging for translational studies
Quantitative benchmarking of nuclear segmentation algorithms in multiplexed immunofluorescence imaging for translational studies Open
View article: Graphical and Interactive Spatial Proteomics Image Analysis Workflow
Graphical and Interactive Spatial Proteomics Image Analysis Workflow Open
Spatial proteomics provides a spatially resolved view of protein expression and localization within cells and tissues by mapping the location and abundance of proteins. There is a need for fully-integrated end-to-end imaging workflows for …
View article: Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa Open
View article: Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses Open
Background Antibodies blocking programmed death (PD)-1 or its ligand (PD-L1) have revolutionized cancer care, but many patients do not experience durable benefits. Novel treatments to stimulate antitumor immunity are needed in the PD-(L)1 …
View article: PD‐L1<sup>+</sup> macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B‐cell lymphoma microenvironment impact CD19 CAR‐T cell immunotherapy efficacy
PD‐L1<sup>+</sup> macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B‐cell lymphoma microenvironment impact CD19 CAR‐T cell immunotherapy efficacy Open
CD19‐targeted chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has transformed the management of relapsed/refractory large B‐cell lymphoma (LBCL), yet durable remissions are observed in less than half of treated patients. The tumor m…
View article: Supplementary Figures from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Supplementary Figures from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Figure S1. Cellular composition of the post-treatment tumor biopsy of patient UPN-03. Figure S2. Gating strategy for multiparameter flow cytometry for UPN-03. Figure S3. Gating strategy for multiparameter flow cytometry for UPN-04.
View article: Table S3 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S3 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S3. Cellular composition of post-infusion timepoints.
View article: Table S3 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S3 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S3. Cellular composition of post-infusion timepoints.
View article: Table S2 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S2 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S2. Differentially expressed TCR-β CDR3 sequences increased at 3 and/or 35 month timepoints in patient UPN-04
View article: Table S1 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S1 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S1. Baseline cytokine levels (prior to lymphodepletion) for UPN-03 and UPN-04.
View article: Table S4 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S4 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S4. Staining panel used for multiplex immunohistochemistry
View article: Data from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Data from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Chimeric antigen receptor (CAR) T-cell therapy produces high response rates in refractory B-cell non–Hodgkin lymphoma, but long-term data are minimal to date. In this study, we present long-term follow-up of a pilot trial testing a CD20-ta…
View article: Supplementary Figures from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Supplementary Figures from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Figure S1. Cellular composition of the post-treatment tumor biopsy of patient UPN-03. Figure S2. Gating strategy for multiparameter flow cytometry for UPN-03. Figure S3. Gating strategy for multiparameter flow cytometry for UPN-04.
View article: Table S4 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S4 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S4. Staining panel used for multiplex immunohistochemistry
View article: Data from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Data from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Chimeric antigen receptor (CAR) T-cell therapy produces high response rates in refractory B-cell non–Hodgkin lymphoma, but long-term data are minimal to date. In this study, we present long-term follow-up of a pilot trial testing a CD20-ta…
View article: Table S1 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S1 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S1. Baseline cytokine levels (prior to lymphodepletion) for UPN-03 and UPN-04.
View article: Table S2 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Table S2 from Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Table S2. Differentially expressed TCR-β CDR3 sequences increased at 3 and/or 35 month timepoints in patient UPN-04
View article: Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy
Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy Open
Chimeric antigen receptor (CAR) T-cell therapy produces high response rates in refractory B-cell non–Hodgkin lymphoma, but long-term data are minimal to date. In this study, we present long-term follow-up of a pilot trial testing a CD20-ta…
View article: Supplementary Figure S1 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S1 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Signature expression of MNP universal genes and selected M-MDSC genes among all identified clusters.
View article: Supplementary Figure S2 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S2 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Transcriptomics analysis demonstrate differences between TAMs and DCs.
View article: Supplementary Figure S5 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S5 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Results of ROC space comparing CD8 percentage, MDSC-Mac/CD8 and Mono-Mac ratios as a in three patients groups stratified by CD8 levels.
View article: Supplementary Table S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Table S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
MNP and M-MDSC gene signatures used for myeloid clusters validation
View article: Supplementary Figure S8 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S8 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Higher levels of S100A8 expressing cells relative to CD8 T cells in responding MCC tumors are associated with shorter duration of response.
View article: Supplementary Figure S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Immune lineage analysis of tumor infiltrating cells, by patient response to immunotherapy.
View article: Supplementary Figure S9 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S9 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Spatial analysis of tumors with high CD8 infiltration did not show different in the proximity or clustering of myeloid cells markers or phenotypes near CD8 T cells between the response groups.
View article: Data from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Data from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Purpose:Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer. Although essentially all MCCs are antigenic through viral antigens or high tumor mutation burden, MCC has a response rate of only approximately 50% to PD-(L)1 blockad…
View article: Supplementary Table S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Table S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
MNP and M-MDSC gene signatures used for myeloid clusters validation
View article: Supplementary Figure S5 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S5 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Results of ROC space comparing CD8 percentage, MDSC-Mac/CD8 and Mono-Mac ratios as a in three patients groups stratified by CD8 levels.
View article: Supplementary Figure S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Supplementary Figure S4 from Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade Open
Immune lineage analysis of tumor infiltrating cells, by patient response to immunotherapy.